A detailed history of Trexquant Investment LP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Trexquant Investment LP holds 44,997 shares of CSTL stock, worth $979,584. This represents 0.02% of its overall portfolio holdings.

Number of Shares
44,997
Previous 11,491 291.58%
Holding current value
$979,584
Previous $247,000 303.24%
% of portfolio
0.02%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$18.06 - $25.3 $605,118 - $847,701
33,506 Added 291.58%
44,997 $996,000
Q4 2023

Feb 09, 2024

SELL
$12.19 - $22.43 $1,682 - $3,095
-138 Reduced 1.19%
11,491 $247,000
Q3 2023

Nov 13, 2023

BUY
$13.28 - $20.3 $154,433 - $236,068
11,629 New
11,629 $196,000
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $711,676 - $1.09 Million
31,616 New
31,616 $825,000
Q2 2021

Aug 12, 2021

SELL
$50.07 - $76.78 $349,588 - $536,077
-6,982 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$58.92 - $97.33 $411,379 - $679,558
6,982 New
6,982 $478,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $572M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.